• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHANG Yuanyuan,OU Yiyang,YE Huirong,WEN Enhui.Meta-analysis of the efficacy and safety of NOACs versus Warfarin in the treatment of cerebral venous sinus thrombosis[J].Journal Of Pharmaceutical Research,2026,45(5):587-595[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1476times   Download 731次 QR Code for this article
Scan with your phone!
NOACs与华法林治疗颅内静脉窦血栓有效性和安全性的Meta分析
常媛媛1,欧逸扬2,叶慧茸1,文恩辉1
Font:Larger+|Default|Smaller-
(1.西安医学院第一附属医院,陕西 西安 710082;2.西安医学院,陕西 西安 710021)
摘要:
目的 系统比较非维生素K抗凝拮抗药(NOACs)与华法林在治疗颅内静脉窦血栓的疗效和安全性。方法 通过计算机检索国内外发表的NOACs与华法林治疗颅内静脉窦血栓的RCTs和前瞻性的队列研究,提取数据后用Review Manager 5.4 软件进行数据处理。结果 根据Meta分析结果显示,使用NOACs治疗颅内静脉窦血栓患者的静脉血栓复发率、静脉血栓部分再通率、静脉血栓完全再通率、死亡发生率、大出血发生率、颅内出血发生率均与使用华法林进行抗凝治疗的患者无显著统计学差异,但良好临床结局优于华法林组。结论 NOACs与华法林在治疗颅内静脉窦血栓(CVST)患者的有效性与安全性相当。
关键词:  颅内静脉窦血栓  直接口服抗凝药  利伐沙班  阿哌沙班  艾多沙班  达比加群  华法林  Meta分析
DOI:10.13506/j.cnki.jpr.2026.05.015
基金项目:
Received Date:May 13, 2025   Revision Date:July 09, 2025   Publication Date:May 29, 2026
Meta-analysis of the efficacy and safety of NOACs versus Warfarin in the treatment of cerebral venous sinus thrombosis
CHANG Yuanyuan1,OU Yiyang2,YE Huirong1,WEN Enhui1
(1. The First Affiliated Hospital of Xi'an Medical University, Xi'an 710082, China;2.Xi'an Medical University, Xi'an 710000, China)
Abstract:
Objective To systematically compare the efficacy and safety of non vitamin K antagonist (NOACs) and warfarin in the treatment of cerebral venous sinus thrombosis.Methods Randomized controlled trials (RCTs) and prospective cohort studies on the treatment of cerebral venous sinus thrombosis with NOACs and warfarin published at home and abroad were retrieved by computer. After the data were extracted, Review Manager 5.4 software was used for data processing.Results According to the results of Meta-analysis, there were no significant statistical differences in the recurrence rate of venous thrombosis, partial recanalization rate of venous thrombosis, complete recanalization rate of venous thrombosis, mortality rate, incidence of major bleeding and incidence of intracranial hemorrhage between patients with cerebral venous sinus thrombosis treated with NOACs and those treated with warfarin for anticoagulation, but the good clinical outcomes of the NOACs group were better than those of the warfarin group.Conclusion The efficacy and safety of NOACs are comparable to those of warfarin in the treatment of patients with cerebral venous sinus thrombosis (CVST).
Key words:  Cerebral venous sinus thrombosis  Direct oral anticoagulants  Rivaroxaban  Apixaban  Edoxaban  Dabigatran  Warfarin  Meta-analysis
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.